MicroRNA-101-mediated Akt activation and estrogen-independent growth
MicroRNAs are gene regulators that work through a posttranscriptional repression mechanism. Dysregulation of microRNA expression could lead to a variety of disorders, in particular, human cancer, and has also been implicated in antihormone therapy resistance. However, little is known whether microRN...
Gespeichert in:
Veröffentlicht in: | Oncogene 2011-02, Vol.30 (7), p.822-831 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | MicroRNAs are gene regulators that work through a posttranscriptional repression mechanism. Dysregulation of microRNA expression could lead to a variety of disorders, in particular, human cancer, and has also been implicated in antihormone therapy resistance. However, little is known whether microRNAs have a role in estrogen-independent growth, leading to tamoxifen resistance in estrogen receptor (ER)-positive tumors. In this study, we use an
in vivo
selection system against a microRNA library using the MCF-7 model and demonstrate that
miR-101
promotes estrogen-independent growth and causes the upregulation of phosphorylated Akt (pAkt) without impacting the ER level or activity. Importantly, although
miR-101
suppresses cell growth in normal estradiol (E2)-containing medium, it promotes cell growth in E2-free medium. Moreover, estrogen deprivation greatly enhances
miR-101
-mediated Akt activation. Finally, we show that MAGI-2 (membrane-associated guanylate kinase), a scaffold protein required for PTEN (phosphatase and tensin homolog) activity, is a direct target for
miR-101
; suppression of MAGI-2 by
miR-101
reduces PTEN activity, leading to Akt activation. Taken together, these results not only establish a role for
miR-101
in estrogen-independent signaling but also provide a mechanistic link between
miR-101
and Akt activation. |
---|---|
ISSN: | 0950-9232 1476-5594 |
DOI: | 10.1038/onc.2010.463 |